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For dialysis patients with bleeding and its associated risk, heparin-free dialysis with periodic saline flushes and regional dialysis anticoagulated with citrate were P atients with uremia who suffer from heparininduced thrombocytopenia (HIT) can not be treated by hemodialysis (dialysis) with unfractionated heparin (UFH) and low-molecular weight heparin (LMWH). Currently, alternatives to heparin, no-heparin protocols, and peritoneal dialysis are proposed as suitable for the treatment of HIT in a clinical setting. Three alternative anticoagulantsdanaparoid, a low-molecular heparinoid; lepirudin, a recombinant desulfatehirudin; and argatroban, a synthetic arginine derivative-are available for treatment with dialysis. 1 In selecting a suitable alternative to heparin, anticoagulants with hepatic excretion, like danaparoid and argatroban rather than renal Medical records of 122 patients with suspected heparin-induced thrombocytopenia on dialysis were reviewed. Method of dialysis in heparin-induced thrombocytopenia patients with bleeding from various causes (including surgical interventions) and how to cope with blood access occlusion induced by heparininduced thrombocytopenia were studied. Of 122 patients, 17 who met the criteria of >30% thrombocytopenia, clots in the extracorporeal circulation, positive for heparin/PF4 complex antibodies, and improvement from heparin-induced thrombocytopenia with the use of an alternative anticoagulant or another strategy for heparin-induced thrombocytopenia were chosen. Argatroban was uneventfully introduced in 12 patients having neither bleeding nor blood access failure. In all, 2 of 5 patients were treated with peritoneal dialysis. The others requiring a regional anticoagulant were given nafamostat mesilate. Argatroban as an alternative provides effectively anticoagulation in patients with heparin-induced thrombocytopenia on dialysis. In patients with heparin-induced thrombocytopenia with bleeding and its associated risk, nafamostat mesilate was an alternative. Peritoneal dialysis also was applied in cases of blood access failure due to heparin-induced thrombocytopenia.
Keywords: heparin-induced thrombocytopenia; argatroban; nafamostat mesilate; peritoneal dialysis selected to avoid systemic heparinization. Otherwise, nafamostat mesilate, a polyvalent synthetic protease inhibitor (molecular weight: 539.58 Da), is applied as a regional anticoagulant in dialysis patients with bleeding risks as an alternative to heparin. 7, 8 First, it was determined what dosages of argatroban were uneventfully used in patients with HIT on intermittent dialysis. Second, it was examined whether temporary peritoneal dialysis was a useful option for patients with HIT on dialysis with blood access failure caused by thrombotic occlusion in the arteriovenous fistula due to HIT. Third, it was clarified whether nafamostat mesilate would be suitable as a regional anticoagulant for patients with HIT with bleeding or bleeding risk in which systemic anticoagulation is considered contraindicated.
Subjects and Methods
Subjects were chosen from 122 suspected patients with HIT who had >30% thrombocytopenia with no other cause and/or clot formation in dialysis under an optimal dose of heparin or LMWH and referred to a clearinghouse for HIT enclosed with written informed consent for a serology test from 2003 to 2005. Seventeen HIT dialysis patients (11 men, 6 women, 67.4 ± 15.1 [mean ± SD] years) who met the following inclusion criteria were retrospectively selected for this survey.
The inclusion criteria added on in the suspected HIT condition were (a) the formation of clots in the extracorporeal circuit, which resulted in a discontinuation of dialysis; (b) positivity for heparin/PF4 complexes antibodies (HIT antibodies) tested by enzymelinked immunosorbent assay (ELISA) (GTI-PF4 ELISA Assay, GTI, Wisconsin); (c) administration of argatroban immediately after suspected HIT with thrombocytopenia and clotting in the circuit; (d) delayed administration of argatroban due to bleeding and its associated risk; (e) blood access failure due to thrombotic occlusion in HIT; and (f) allowing the same hollow-fiber dialyzer and blood flow rate in the dialysis session every 2 days. In addition to the ELISA, a platelet aggregation assay was performed by adding patient serum or plasma to normal platelet-rich plasma in a conventional platelet aggregometer. A positive result showed more than 20% aggregation in the presence of low-dose heparin and inhibition of aggregation at a high dose of heparin. 9 In 5 of 17 patients with HIT, the use of argatroban was either delayed (n = 2) or discontinued with the onset of overt bleeding and its risk of worsening (n = 3). The former could not receive dialysis due to immature blood access and were treated with temporally peritoneal dialysis until fistula maturation of vascular access surgery and subsequently argatroban was introduced. The latter 3 patients on dialysis had bleeding from the urinary tract and its risk: postcardiovascular surgery in 2 cases and postorgan biopsy in 1 case. As these patients on dialysis had contraindications of systemic anticoagulation, nafamostat mesilate as a regional anticoagulant was used at the time of bleeding and its associated risks. The drug is used as a regional anticoagulant in dialysis to reduce bleeding complications because of its short half-life of 5 to 8 minutes. 10 As soon as bleeding and its associated risk were completely removed, these patients were treated with argatroban. Therefore, those 5 patients were analyzed separately.
Results

Argatroban Dosing in Patients With HIT on Dialysis
Twelve patients with HIT on dialysis with no bleeding and no risk of bleeding were studied as to what dose to use in the dialysis. Although argatroban was started with a bolus of 5-10 mg (8.8 ± 2.3 mg [mean ± SD]) and continuous infusion of 0.26 ± 0.17 mg/kg/h in the acute phase of HIT until recovery for thrombocytopenia of HIT, the dosage was readjusted with activated partial thromboplastin time (APTT) to 1.5-2.5 times the baseline after recovery from thrombocytopenia. Those patients with HIT had no complications with new thrombosis and no clots in the circuit, and no bleeding in the course of dialysis ( Table 1 ). The dose of argatroban did not need to be adjusted between before and after recovery of thrombocytopenia. Also, the dose of argatroban did not significantly differ with gender or between diabetics and nondiabetics. A bolus of 5 to 20 mg and continuous infusion of around 0.01(min)-0.55(max) mg/kg/h of argatroban were enough to maintain fluidity in the circuit through the acute and postacute stages of HIT.
Peritoneal Dialysis in Patients With HIT
In all, 2 of 17 patients with HIT were treated with peritoneal dialysis due to blood access thrombosis in the arteriovenous fistula. No worsening effects on the development of thrombocytopenia and new thrombosis during peritoneal dialysis, and no complication of bleeding during the peritoneal dialysis were observed. Blood access maturation 2 weeks from arteriovenous fistula surgery was obtained, and then argatroban sessions were started with a bolus of 5 mg and continuous infusion of 0.12 or 0.16 mg/kg/h, respectively. These sessions were uneventful with no thrombosis and no worsening of the bleeding risk ( 
Nafamostat Mesilate Anticoagulation During Bleeding and Its Risk
In 3 of 17 patients with HIT requiring heparin-free dialysis, nafamostat mesilate was applied in 5 episodes for bleeding and its associated risk immediately after surgical interventions including cardiovascular surgery and organ biopsy. Nafamostat mesilate with a bolus of 20 mg and continuous infusion of 0.6, 0.2, and 0.8 mg/kg/h, respectively, was applied to dialysis in each session with these episodes, under prolongation of >200 seconds of activated clotting time (ACT) at the inlet to the dialyzer. Each dialysis session with nafamostat mesilate was performed with neither worsening bleeding nor clotting in the circuit ( Table 2, 
panel b).
A vascular-surgery patient (no. 1 in Table 2 , panel b) with postoperative renal failure was treated with dialysis by UFH anticoagulation on every other day. In the third dialysis session, HIT developed with generalized petechiae or ecchymoses, thrombocytopenia, and clots in the circuit. To avoid worsening of bleeding, regional dialysis with nafamostat mesilate as a bolus of 20 mg, and continuous infusion of 0.6 mg/kg/h was administered in the next 7 sessions. After a recovery of the platelet count and subsidence of the bleeding, anticoagulant in dialysis was changed to argatroban with a bolus of 10 mg and continuous infusion of 0.2 mg/kg/h. The use of argatroban was continued until the disappearance of HIT antibodies about 10 months later.
A patient with HIT (no. 2 in Table 2 , panel b) on dialysis was subjected to cardiac surgery for atrial septal defect. The open heart operation was carried out with argatroban as a bolus of 0.4 mg/kg and continuous infusion of 0.6 mg/kg/h adjusting the level of ACT over 350 seconds for the 5-hour cardiopulmonary bypass. The dose of argatroban for cardiac surgery was based on the diagnostic and treatment guidelines of HIT in the cardiovascular patients. 11 In 3 postoperative dialysis sessions, regional anticoagulation with nafamostat mesilate as a bolus of 10 mg and continuous infusion of 0.2 mg/kg/h was used to prevent postoperative bleeding. Following the 9 sessions, 462 Clinical and Applied Thrombosis/Hemostasis / Vol. 14, No. 4, October 2008 argatroban as a bolus of 10 mg and continuous infusion of 0.2 mg/kg/h was given until the patient was discharged. A patient with diabetes (no. 3, in Table 2 , panel b) on dialysis with LMWH developed HIT with thrombocytopenia and clotting in the circuit in the eighth session. Microscopic hematuria after cystoscopy performed the day before was found in the ninth session, and the session indicating the regional anticoagulant was uneventfully performed with nafamostat mesilate as a bolus of 10 mg and continuous infusion of 0.8 mg/kg/h. The next 2 sessions were conducted with argatroban as a bolus of 10 mg and continuous infusion of 0.3 mg/kg/h. The patient complained of gross hematuria after bladder biopsy and in the subsequent 2 sessions was dialyzed with the same dose of nafamostat mesilate. After the disappearance of hematuria, argatroban sessions were conducted until 10 months after the disappearance of HIT antibodies.
Discussion
In patients with uremia treated with dialysis, UFH is the most commonly used anticoagulant for preventing clots in the circuit. Heparin-induced thrombocytopenia often induces clotting in the circuit and drives the session to be discontinued. Whenever HIT is suspected, the use of heparin must cease and an alternative anticoagulant immediately started. Also, heparin-free dialysis or dialysis anticoagulated with citrate may be applied to patients with HIT on dialysis. Peritoneal dialysis may be indicated in thrombotic occlusion in arteriovenous fistula due to HIT. In this study, an improvement in uremia in 2 patients with HIT was obtained by ambulatory peritoneal dialysis until maturation of blood access surgery for arteriovenous fistula. Subsequent dialysis with argatroban was uneventfully started through the fistula. Peritoneal dialysis was indicated when heparin-free dialysis could not be performed in a patient with HIT with blood access failure. Now, 3 alternatives to heparin, argatroban, lepirudin, and danaparoid, are generally used for HIT on dialysis. 12 Dose adjustment of lepirudin is often difficult in patients with uremia on dialysis because the dose is influenced by renal clearance and the generation of antilepirudin antibodies. 13 Danaparoid, a low-molecular weight heparinoid also cleared from the kidneys, is used for the treatment of HIT requiring dialysis. 14, 15 However, danaparoid, because of its cross-reactivity with UFH, has been withdrawn from use in the United States and the United Kingdom and contraindicates to use on patients with HIT in Japan. Argatroban is a direct thrombin inhibitor with hepatic excretion, and its dose adjustment is relatively easy in dialysis patients with no impaired hepatic functions. Therefore, argatroban provides effective anticoagulation in patients with HIT requiring renal replacement therapy including dialysis. 16 In this study, 2 alternative anticoagulants, argatroban and nafamostat mesilate, were introduced in patients with HIT requiring dialysis. Argatroban as a systemic anticoagulant was applied in 12 patients with HIT with no bleeding risk. A bolus of 5 or 10 mg and continuous infusion of 0.07 (minimum) to 0.55 (maximum) mg/kg/h was enough to maintain fluidity in the circuit. In 5 patients with uremia undergoing renal replacement therapy, argatroban was reported to be infused continuously at a dose of 0.03 to 0.12 mg/kg/h. 17 Although the dose was smaller than that obtained from this study, no patients suffered from any side effects including clots in the dialyzer. It is certainly suggested that APTT monitoring would be a suitable way to find the optimal dose of argatroban for an individual patient. Once a patient with HIT on dialysis has suffered from bleeding, nafamostat mesilate as a regional anticoagulant could be chosen as an alternative to argatroban.
When abrupt clotting occurs in the circuit in a patient with HIT on dialysis, an alternative anticoagulant to heparin would be immediately given to prevent the clotting and to continue the session. However, systemic anticoagulants are contraindicated in patient with HIT who have overt bleeding accompanied by a decrease in hemoglobin or hematocrit such as bleeding from the gastrointestinal or urinary tract and risks of bleeding after organ biopsy, recent stroke, or brain and cardiovascular surgery. In these patients with HIT on dialysis, it is necessary to change the form of anticoagulation from systemic to regional to avoid a worsening of the bleeding and its associated risk. Nafamostat mesilate is characterized by a short half-life and about 40% of the drug is removed by the dialyzer. Therefore, <4% of nafamostat mesilate infused in the extracorporeal circuit enters into the systemic circulation. Nafamostat mesilate entered in the circulation has no influence on the blood coagulation cascade. 18 In the present study, 2 patients with HIT with postoperative bleeding risk were anticoagulated with nafamostat mesilate during dialysis. It is suggested that nafamostat mesilate can be effective as a regional anticoagulant for HIT requiring dialysis to avoid worsening of bleeding and its associated risks. After the disappearance of the bleeding and its risks through regional dialysis with nafamostat mesilate for a short period, argatroban will be reused without problems.
